Acquisition

Angeion Group's appointment of a legal marketing veteran isn't just a new hire; it's a calculated move to challenge rivals and dominate its niche.

LRN appoints Bob Lemmond as CEO, a strategic move signaling a deeper push into data-driven ethics amid rising AI regulations and market complexity.

Eli Lilly's takeover of Adverum signals a major push into ocular gene therapy. Can a one-time injection for vision loss disrupt a multi-billion dollar market?

A new military satellite project in the Arctic is about more than defence. It's a test for a new procurement model and a major bet on Canadian tech.

Secure identity firm CLEAR lands a major CMS contract to overhaul Medicare.gov's login system, signaling a strategic push into the government sector.

A new federal hemp ban is set to fail, warns a CRS report. Experts say a lack of funding and data infrastructure could create a dangerous black market.

A famed NYC pub's arrival signals a new era for Atlanta's downtown, as the massive Centennial Yards project races to redefine the city for a global stage.

Beyond a simple product launch, a strategic acquisition is fueling innovations in drug delivery that could transform patient care for millions worldwide.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

PTC launches its Arena AI Engine to automate compliance and document review, offering a strategic advantage for complex defense and aerospace supply chains.

A home remodeler is a top IT workplace. The defense sector must learn from its model for talent development, which holds strategic national security lessons.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

A new partnership aims to fix the broken music industry with a global commerce engine and advanced AI, giving artists true ownership of their careers.

Beyond transmissions, Allison's deep investment in India is a blueprint for global firms fueling defense, mining, and export growth. Here's why it matters.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

A top FinTech firm's new product chief reveals a strategic roadmap for taming complexity that the defense and space sectors cannot afford to ignore.

A mandatory disclosure from a Boston investment giant reveals its position in a $1.4B merger. What does it signal for the future of the auto industry?

A French bank's cryptic filing on UK's Just Group reveals a high-stakes hedging strategy amid a major takeover. What does it really signal for the deal?

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.